BACKGROUND: Allogeneic hematopoietic cell transplantation provides a reliable method for inducing tolerance toward solid organ grafts. However, this procedure can result in graft-versus-host disease, thereby limiting its application. Here, we test the hypothesis that mixed chimerism can be intentionally reverted to host hematopoiesis without rejection of a kidney graft. METHODS: Recipient dogs were given 2-Gy total-body irradiation (TBI) before and a short course of immunosuppression after marrow infusion from dog leukocyte antigen-identical littermates. All dogs achieved stable mixed chimerism. After a mean of 20 weeks, one cohort of dogs received kidney transplants from their respective marrow donors. Subsequently, recipients were reconditioned with 2-Gy TBI and given autologous granulocyte colony-stimulating factor-mobilized leukocytes (recipient leukocyte infusion [RLI]) that had been collected before marrow transplantation. RESULTS: Dogs receiving a second TBI and RLI without a kidney transplant rejected their donor hematopoietic graft within 3 weeks. Dogs that received kidney grafts, followed by a second TBI and RLI, rejected their marrow graft without rejecting their transplanted kidneys for periods greater than 1 year. CONCLUSION: Mixed chimerism may be clinically reverted to 100% recipient without rejection of a kidney allograft. This finding may have application toward minimizing the risk of graft-versus-host disease in solid organ transplantation patients given hematopoietic cell transplantation from human leukocyte antigen-identical donors.
BACKGROUND: Allogeneic hematopoietic cell transplantation provides a reliable method for inducing tolerance toward solid organ grafts. However, this procedure can result in graft-versus-host disease, thereby limiting its application. Here, we test the hypothesis that mixed chimerism can be intentionally reverted to host hematopoiesis without rejection of a kidney graft. METHODS: Recipient dogs were given 2-Gy total-body irradiation (TBI) before and a short course of immunosuppression after marrow infusion from dog leukocyte antigen-identical littermates. All dogs achieved stable mixed chimerism. After a mean of 20 weeks, one cohort of dogs received kidney transplants from their respective marrow donors. Subsequently, recipients were reconditioned with 2-Gy TBI and given autologous granulocyte colony-stimulating factor-mobilized leukocytes (recipient leukocyte infusion [RLI]) that had been collected before marrow transplantation. RESULTS:Dogs receiving a second TBI and RLI without a kidney transplant rejected their donor hematopoietic graft within 3 weeks. Dogs that received kidney grafts, followed by a second TBI and RLI, rejected their marrow graft without rejecting their transplanted kidneys for periods greater than 1 year. CONCLUSION: Mixed chimerism may be clinically reverted to 100% recipient without rejection of a kidney allograft. This finding may have application toward minimizing the risk of graft-versus-host disease in solid organ transplantation patients given hematopoietic cell transplantation from human leukocyte antigen-identical donors.
Authors: Murad Y Yunusov; Christian S Kuhr; George E Georges; William J Hogan; Anna G Taranova; Marina Lesnikova; Yang-Soo Kim; Kraig Abrams; Billanna Hwang; George E Sale; Barry Storer; Rainer Storb; Richard A Nash Journal: Transplantation Date: 2006-09-15 Impact factor: 4.939
Authors: Thomas R Spitzer; Megan Sykes; Nina Tolkoff-Rubin; Tatsuo Kawai; Steven L McAfee; Bimalangshu R Dey; Karen Ballen; Francis Delmonico; Susan Saidman; David H Sachs; A Benedict Cosimi Journal: Transplantation Date: 2011-03-27 Impact factor: 4.939
Authors: Anita N Stumpf; Edith D van der Meijden; Cornelis A M van Bergen; Roel Willemze; J H Frederik Falkenburg; Marieke Griffioen Journal: Blood Date: 2009-08-25 Impact factor: 22.113
Authors: Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: R A Nash; M Yunosov; K Abrams; B Hwang; C Castilla-Llorente; P Chen; A S Farivar; G E Georges; R C Hackman; W J E Lamm; M Lesnikova; H D Ochs; J Randolph-Habecker; S F Ziegler; R Storb; B Storer; D K Madtes; R Glenny; M S Mulligan Journal: Am J Transplant Date: 2009-05 Impact factor: 8.086
Authors: Scott S Graves; William Hogan; Christian S Kuhr; Razvan Diaconescu; Michael A Harkey; George E Georges; George E Sale; Eustacia Zellmer; Szczepan W Baran; Szczepan Baran; Christoph Jochum; Brad Stone; Rainer Storb Journal: Blood Date: 2007-03-16 Impact factor: 22.113
Authors: Steven Lawrence Rosinski; Brad Stone; Scott S Graves; Deborah H Fuller; Stephen C De Rosa; Gregory A Spies; Gregory J Mize; James T Fuller; Rainer Storb Journal: Transplantation Date: 2015-10 Impact factor: 4.939
Authors: Jeffrey M Dodd-O; Sudipto Ganguly; Ante Vulic; Angela Panoskaltsis-Mortari; John F McDyer; Leo Luznik Journal: Transplantation Date: 2016-12 Impact factor: 4.939
Authors: Jeff Chang; Scott S Graves; Tiffany Butts-Miwongtum; George E Sale; Rainer Storb; David Woodbridge Mathes Journal: Transplantation Date: 2016-12 Impact factor: 4.939
Authors: Chul-Woo Pyo; Michael A Harkey; Beverly Torok-Storb; Rainer Storb; Ruihan Wang; Alexander S Thomas; Wyatt C Nelson; Daniel E Geraghty Journal: HLA Date: 2022-08-09 Impact factor: 8.762
Authors: David W Mathes; Jeff Chang; Billanna Hwang; Scott S Graves; Barry E Storer; Tiffany Butts-Miwongtum; George E Sale; Rainer Storb Journal: Transplantation Date: 2014-07-27 Impact factor: 4.939